Assessing the Effect of Pomalidomide or Carfilzomib Treatment on Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Gupta, Shaloo [1 ]
Clancy, Zoe [2 ]
Copher, Ronda [2 ]
Rosenberg, Aaron Seth [3 ]
机构：
[1] Kantar, New York, NY USA
[2] Celgene Corp, Summit, NJ USA
[3] Univ Calif Davis, Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA 95817 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
Multiple myeloma; Patient Reported Measures; Pomalidomide;
D O I：
10.1016/j.clml.2019.09.443
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-117
引用
收藏
页码：E268 / E269
页数：3
相关论文
共 50 条
  • [31] Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab
    Richter, Joshua
    Anupindi, Vamshi Ruthwik
    Yeaw, Jason
    Kudaravalli, Suneel
    Zavisic, Stojan
    Shah, Drishti
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 395 - 409
  • [32] Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
    Cohen, Alexa
    Spektor, Tanya M.
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall
    Eshaghian, Shahrooz
    Nassir, Youram
    Maluso, Tina
    Swift, Regina A.
    Vescio, Robert
    Berenson, James R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 60 - 70
  • [33] Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma
    Conticello, Concetta
    Parisi, Marina
    Romano, Alessandra
    Calafiore, Valeria
    Ancora, Flavia
    La Fauci, Alessia
    Consoli, Maria Letizia
    Di Raimondo, Francesco
    FUTURE ONCOLOGY, 2017, 13 (05) : 3 - 6
  • [34] Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
    Hungria, Vania
    Weisel, Katja
    Currie, Brooke
    Perera, Sue
    Sule, Neal
    He, Wei
    Davy, Katherine
    McKeown, Astrid
    Sapra, Sandhya
    Nelsen, Linda
    Li, Mary
    Barale, Sophie
    Boyle, Julia
    McPoyle, Kaytlyn
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S505
  • [35] An elevated systemic inflammation index is related to an inferior response to pomalidomide and dexamethasone treatment in patients with relapsed and refractory multiple myeloma
    Mikulski, Damian
    Robak, Pawel
    Mirocha, Grzegorz
    Ryzewska, Wiktoria
    Stanczak, Kamila
    Okonski, Karol
    Koscielny, Kacper
    Robak, Tadeusz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2023, 27 (03): : 139 - 146
  • [36] Assessment tools for patient-reported outcomes in multiple myeloma
    Wang, Ting
    Lu, Qin
    Tang, LeiWen
    SUPPORTIVE CARE IN CANCER, 2023, 31 (07)
  • [37] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James
    Martinez, Daisy
    Spektor, Tanya
    Sanchez, Armando
    Ghermezi, Matthew
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E249 - E250
  • [38] Assessment tools for patient-reported outcomes in multiple myeloma
    Ting Wang
    Qin Lu
    LeiWen Tang
    Supportive Care in Cancer, 2023, 31
  • [39] Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
    Fotiou, Despina
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [40] A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
    Yashar, David
    Spektor, Tanya M.
    Martinez, Daisy
    Ghermezi, Matthew
    Swift, Regina A.
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    Berenson, James R.
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 975 - 983
12345